Close

PREVIOUS EDITIONS

The Nanomedicine Award started in 2013

In 2015 the award review board agreed to distinguish two excellent projects. The winners were announced during a Nanomedicine Award Ceremony hold at Bio-Europe conference in Munich, November 3rd 2015.

Nanomedicine Early Clinical Stage Project Award

MerckKGaA Company (Germany), with a project aiming to develop a nanomedicine oncology product for mucosal therapeutic vaccination: “Inhalable chitosan-basednano-in-microparticles for mucosal therapeutic vaccination”, presented by Dr.Andrea Hanefeld (http://www.merck.de/de/index.html). 

Best Nanomedicine Product-Deal Award

CelatorPharmaceuticals, Inc., (US-Canada) a clinical-stage biopharmaceutical company with a project focused on an anti-cancer nano-scale drug combination: “CPX-351, a novel synergistic fixed-ratioliposome formulationco-encapsulating Cytarabine and Daunorubicin, increases the survival of patients with Acute Myelogenous Leukemia”, presented by Dr. Lawrence Mayer, (http://www.celatorpharma.com). 

The EBD group, Nanobiotix and the Nanomedicines Alliance were the sponsors of this event which was jointly organized by ETPN and ENATRANS.

Andrea Hanefeld, PhD, of Merck; and Lawrence D. Mayer, PhD, of Celator Pharmaceuticals Inc.

In 2013 the award review board agreed to distinguish two excellent projects. The winners were announced during a Nanomedicine panel hold at Bio-Europe conference in Vienna, November 4th 2013.

Nanodiagnostic Category

EndomagneticsLtd (United Kingdom), with a project aiming to develop an advanced magnetic sensing technology to increase access to the standard of care in breast cancer stagingby providing an alternative approach to locating sentinel lymph nodes. Dr Eric Mayes, CEO of Endomagnetics Ltd received the award. (www.endomagnetics.com). 

Regenerative medicine Category

I-CARE project, Integrative nano-Composites And Regeneration of the Eye, from Linköping University, aiming to develop a regenerative medicine‐based treatment for Corneal Herpes Simplex Keratitis (HSK), that simultaneously treat the disease while regenerating the damaged cornea. May Griffith, Professor at Linköping University, Department of Clinical and Experimental Medicin received the award. www.hu.liu.se/igen/griffith-may?l=en 

Award winners benefited from a full registration (including partnering) for BIO-Europe 2013 and presented their application in a 5-minute speech at the Nanomedicine Panel Discussion during the event. In addition, the winners were granted a 15-minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year’s free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board for experts’ advice and guidance.

The EBD group and Nanobiotix were the sponsors of this event which was organized by ETPN.